0

Category: Spotlight

Eugene Braunwald, MD Joins Roster of Expert Faculty for The 12th Annual CMHC

Dr. Braunwald, Professor at Harvard Medical School, is a world-renowned expert in the field of cardiovascular medicine and is believed to be the most frequently cited author in the field of cardiology, with more than 1000 publications in peer-reviewed journals. His landmark research includes the identification of hypertrophic cardiomyopathy as a clinical entity. As Founder and Chairman of the TIMI Study Group, one of their many achievements was the PROVE-IT TIMI 22 Trial, which demonstrated the benefit of intensive reduction of LDL cholesterol by statin therapy. Dr. Braunwald will be joining a panel at the 12th Annual CMHC that includes Drs. Christie Ballantyne, Paul Ridker, and Marc Sabatine to discuss the clinical trials FOURIER, REVEAL, and CANTOS.

Update and Clinical Implications of the SPRINT Trial

The SPRINT trial created both excitement and controversy in the medical community when it was realized aggressive blood pressure lowering to a target of 120 mmHg resulted in significant reductions in cardiovascular events and all-cause mortality. These reductions were seen in all of SPRINT’s subgroups including those older than age 75, persons with previous CAD, and those with chronic kidney disease. In her Keynote presentation, “Update and Clinical Implications of the SPRINT Trial,” Suzanne Oparil, MD, one of the principal investigators of the trial, will discuss the benefits seen in SPRINT as well as its caveats while touching on some of the ongoing substudies, including a cost-effectiveness analysis and a mind outcomes study examining the question of whether aggressive blood pressure lowering preserves cognitive function and brain structure.